|
|
Article: Positive two-year data for ALK-Abello's Grazax.(preventing grass pollen allergy)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- March 5, 2007
CopyrightCOPYRIGHT 2007 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Danish drugmaker ALK-Abello has reported strong top-line results from the second treatment year in a long-term study of Grazax, its tablet-based vaccine against grass pollen allergy. According to the firm, the agent showed increased clinical effect and immunological changes in the second treatment year, supporting expectations of a progressive effect with long-term treatment.
The data, which were presented at the annual conference of the American Academy of Allergy, Asthma and ...